Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026)
Tilray Brands (TLRY) reported Income from Non-Controlling Interests of $1.3 million for Q1 2026, up 132.67% on a YoY basis from $575482.1 in Q1 2025, and down 5.84% quarter-over-quarter from $1.4 million in Q4 2025.
Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Tilray Brands has reported Income from Non-Controlling Interests for 7 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 132.67% year-over-year to $1.3 million; the trailing twelve-month figure through Feb 2026 stood at $10.2 million (down 34.62% YoY), and the FY2025 full-year result was $5.4 million, down 76.19% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $1.3 million, down from $1.4 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $20.3 million in Q2 2022, with the low at -$12.3 million in Q1 2024.
- Historically, Income from Non-Controlling Interests has averaged $4.2 million across 5 years, with a median of $2.8 million in 2023.
- The largest YoY upside for Income from Non-Controlling Interests was 50146.88% in 2024 against a maximum downside of 704.85% in 2024.
- Tilray Brands' Income from Non-Controlling Interests stood at $7.3 million in 2022, then plunged by 61.36% to $2.8 million in 2023, then sank by 128.99% to -$819000.0 in 2024, then surged by 273.63% to $1.4 million in 2025, then fell by 5.84% to $1.3 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Tilray Brands | - | - | 54.95 Mn | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.34 Mn |
| Nov 30, 2025 | 1.42 Mn |
| Aug 31, 2025 | 1.84 Mn |
| May 31, 2025 | 5.65 Mn |
| Feb 28, 2025 | -4.10 Mn |
| Nov 30, 2024 | -819,000.00 |
| Aug 31, 2024 | 4.51 Mn |
| May 31, 2024 | 16.08 Mn |
| Feb 29, 2024 | -12.28 Mn |
| Nov 30, 2023 | 2.83 Mn |
| Aug 31, 2023 | 15.82 Mn |
| May 31, 2023 | 32,000.00 |
| Feb 28, 2023 | -1.53 Mn |
| Nov 30, 2022 | 7.31 Mn |
| Aug 31, 2022 | 3.84 Mn |
| May 31, 2022 | 20.34 Mn |
| Feb 28, 2022 | 9.29 Mn |
| Nov 30, 2021 | -1.02 Mn |
| Aug 31, 2021 | 7.05 Mn |
| May 31, 2021 | -6.72 Mn |